Prognostic and predictive significance of p53, EGFr, Ki-67 in larynx preservation treatment

Reports of Practical Oncology and Radiotherapy

Volumn 15, Issue 4, 2010, Pages 87-92

  Małecki, Krzysztof ^a   Gliński, Bogdan ^a   Mucha Małecka, Anna ^a   Ryś, Janusz ^a   Kruczak, Anna ^a   Roszkowski, Krzysztof ^b   Urbańska Gasiorowska, Marta ^c   Hetnał, Marcin ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Regional Oncology Centre Bydgoszcz   (Poland)

^c Ludwik Rydygier Speciality Hospital in Krakow   (Poland)

Author keywords

EGFr; Induction chemotherapy; Ki 67; Larynx preservation; P53

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHARYNX CANCER; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; LARYNX CANCER; LARYNX PRESERVATION; MALE; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 77955845457     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rpor.2010.06.001     Document Type: Article

References (33)

1. Forastiere A., Trotti A., Koch W., et al. Head and neck cancer. N Engl J Med 2001, 345(26):1890-1900.
2. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991, 324(24):1685-1990. Department of Veterans Affairs Laryngeal Cancer Study Group.
3. Lefebvre J.L., Chevalier D., Luboinski B., et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996, 88(13):890-899.
4. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349(22):2091-2098.
5. Forastiere A.A., Maor M., Weber R.S., et al. Long-term results of intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proc Am Soc Clin Oncol 2006, 24, abstr:5517.
6. Hollstein M., Rice K., Greenblatt M.S., et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994, 22(17):3551-3555.
7. Bradford C.R., Zhu S., Wolf G.T., et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg 1995, 113(4):408-412.
8. Bradford C.R., Wolf G.T., Carey T.E., et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg 1999, 121:534-538.
9. Osman I., Sherman E., Singh B., et al. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 2002, 20(13):2980-2987.
10. Santini J., Formento J.L., Francoual M., et al. Characterization, quantification, and potential clinical value of epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991, 18(2):132-139.
11. Dassonville O., Formento J.L., Francoual M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993, 11(10):1873-1878.
12. Maurizi M., Almadori G., Ferrandina G., et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996, 74(8):1253-1257.
13. Grandis J.R., Melhem M.F., Gooding W.E., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-832.
14. Etienne M.C., Pivot X., Formento J.L., et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 1999, 79(11-12):1849-1864.
15. Baselga J., Norton L., Masui H., et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993, 85(16):1327-1333.
16. Fan Z., Baselga J., Masui H., et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993, 53(19):4637-4642.
17. Bonner J.A., Maihle N.J., Folven B.R., et al. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 1994, 29(2):243-247.
18. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59(8):1935-1940.
19. Raybaud-Diogene H., Fortin A., Morency R., et al. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol 1997, 15(3):1030-1038.
20. Homma A., Furuta Y., Oridate N., et al. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 1999, 5:801-806.
21. Lavertu P., Adelstein D.J., Myles J., et al. p53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy. Laryngoscope 2001, 111(11 Pt 1):1878-1892.
22. Couture C., Raybaud-Diogene H., Tetu B., et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002, 94(3):713-722.
23. Mielcarek-Kuchta D., Olofsson J., Golusinski W. p53, Ki67 and cyclin D1 as prognosticators of lymph node metastases in laryngeal carcinoma. Eur Arch Otorhinolaryngol 2003, 260(10):549-554.
24. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 1981, 47(1):207-214.
25. Pivot X., Magne N., Guardiola E., et al. Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol 2005, 41(3):320-327.
26. Brown D.C., Gatter K.C. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990, 17(6):489-503.
27. Golusinski W., Olofsson J., Szmeja Z., et al. A comprehensive analysis of selected diagnostic methods with respect to their usefulness in evaluating the biology of neoplastic cells in patients with laryngeal cancer. Eur Arch Otorhinolaryngol 1999, 256(6):306-311.
28. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355(9208):949-955.
29. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62(24):7350-7356.
30. Pfreundner L., Hoppe F., Willner J., et al. Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas-a possibility for organ preservation. Radiother Oncol 2003, 68:163-170.
31. Pointreau Y., Garaud P., Chapet S., et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009, 101(7):498-506.
32. Bonner J.A., Harari P.M., Giralt J., et al. Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx. Proc Am Soc Clin Oncol 2005, 23, abstr:5533.
33. Bernier J., Bentzen S.M. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 2003, 39(5):560-571.